Giulia Pasello

TL;DR: In this paper , a multicenter Italian study aimed to evaluate whether the COVID-19 outbreak had an impact on access to cancer diagnosis and treatment of lung cancer patients compared with pre-pandemic time.

TL;DR: Clinical studies are focused on the main clinical studies and overview the results of different chemotherapy regimens in the neoadjuvant treatment of MPM, which shows high refractoriety to systemic treatment, single-modality treatment was generally ineffective and did not achieve higher results than supportive care.

TL;DR: A simple and reproducible multiparametric PGS effectively predicted survival in patients with MPM and was effective even in subgroup analysis (epithelioid, biphasic, and sarcomatoid tumors).

TL;DR: A critical summary of recent liquid biopsy-based studies aimed at discovering novel blood-based circulating biomarkers for the early diagnosis and prognostic stratification of MPM patients is provided.

TL;DR: The introduction of new biologic drugs like vorinostat, bortezomib, everolimus and temsirolimus, in the treatment of MPM finds a strong rationale, and Tyrosine kinase inhibitors targeting growth factors and angiogenesis inhibitors like bevacizumab are among the most promising agents under evaluation in clinical trials.